Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lees

Showing results (291-300 of 804) with videos related to

Pageof 81
Sort By:
Journal of Veterinary Pharmacology and Therapeutics|August 9, 2016
Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calfP-L Toutain, T Potter, L Pelligand, et al.
The Journal of Biological Chemistry|March 5, 1987
Isolation and characterization of an abundant and novel 22-kDa protein (SM22) from chicken gizzard smooth muscleJ P Lees-Miller, D H Heeley, L B Smillie, et al.
The British Veterinary Journal|March 1, 1991
Pharmacodynamics and pharmacokinetics of miloxicam in the horseP Lees, A D Sedgwick, A J Higgins, et al.
Heart Rhythm|July 30, 2005
Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees CJiqing Guo, Shu Zhan, James P Lees-Miller, et al.
The Veterinary Record|March 14, 2013
Pharmacodynamics of florfenicol for calf pneumonia pathogensJ Illambas, T Potter, P Sidhu, et al.
Research in Veterinary Science|December 17, 2009
In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative studyJ N King, C Rudaz, L Borer, et al.
Journal of Veterinary Pharmacology and Therapeutics|April 2, 2003
In vitro and ex vivo effects of the phosphodiesterase 4 inhibitor, rolipram, on thromboxane production in equine bloodK J Rickards, C P Page, P Lees, et al.
Veterinary Journal (London, England : 1997)|March 6, 2003
Ketoprofen in the cat: pharmacodynamics and chiral pharmacokineticsP Lees, P M Taylor, F M Landoni, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 4, 2007
Utilizing protein phosphatase inhibitors to define PP2A as a regulator of ataxia-telangiectasia mutatedAaron A Goodarzi, Pauline Douglas, Greg B G Moorhead, et al.
Journal of Veterinary Pharmacology and Therapeutics|June 1, 1996
A study of the effect of a platelet activating factor (PAF) receptor antagonist on antigen challenge of horses with chronic obstructive pulmonary diseaseK A Marr, S M Fairbairn, C P Page, et al.
Pageof 81

Showing results (291-300 of 804) with videos related to

Sort By:
Pageof 81
Journal of Veterinary Pharmacology and Therapeutics|August 9, 2016
Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calfP-L Toutain, T Potter, L Pelligand, et al.
The Journal of Biological Chemistry|March 5, 1987
Isolation and characterization of an abundant and novel 22-kDa protein (SM22) from chicken gizzard smooth muscleJ P Lees-Miller, D H Heeley, L B Smillie, et al.
The British Veterinary Journal|March 1, 1991
Pharmacodynamics and pharmacokinetics of miloxicam in the horseP Lees, A D Sedgwick, A J Higgins, et al.
Heart Rhythm|July 30, 2005
Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees CJiqing Guo, Shu Zhan, James P Lees-Miller, et al.
The Veterinary Record|March 14, 2013
Pharmacodynamics of florfenicol for calf pneumonia pathogensJ Illambas, T Potter, P Sidhu, et al.
Research in Veterinary Science|December 17, 2009
In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative studyJ N King, C Rudaz, L Borer, et al.
Journal of Veterinary Pharmacology and Therapeutics|April 2, 2003
In vitro and ex vivo effects of the phosphodiesterase 4 inhibitor, rolipram, on thromboxane production in equine bloodK J Rickards, C P Page, P Lees, et al.
Veterinary Journal (London, England : 1997)|March 6, 2003
Ketoprofen in the cat: pharmacodynamics and chiral pharmacokineticsP Lees, P M Taylor, F M Landoni, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 4, 2007
Utilizing protein phosphatase inhibitors to define PP2A as a regulator of ataxia-telangiectasia mutatedAaron A Goodarzi, Pauline Douglas, Greg B G Moorhead, et al.
Journal of Veterinary Pharmacology and Therapeutics|June 1, 1996
A study of the effect of a platelet activating factor (PAF) receptor antagonist on antigen challenge of horses with chronic obstructive pulmonary diseaseK A Marr, S M Fairbairn, C P Page, et al.
Pageof 81